Safety Study of Acellular Tissue Engineered Vessel for Coronary Artery Bypass

Inclusion criteria

• . Patient with limited quantity of good quality saphenous vein graft (SVG) for planned operation per the surgeon discretion.
• . Bypass to at least two coronary arteries (CA); primary target shall be an Internal mammary artery (IMA) bypass to the Left anterior descending (LAD) artery, and one IMD to a secondary target CA that:
• . Male or female patients between the ages of 45 and 75 years inclusive.
• . Elective patient, selected and accepted by the local Heart Team and confirmed by the Sponsor's Screening Committee for an on-pump full sternotomy coronary artery bypass grafting (CABG) surgery.
• . Female subjects must be of non-childbearing potential, which is defined as post-menopausal (at least 1 year without menses prior to Screening) or documented surgically sterile or post hysterectomy (at least 1 month prior to Screening).
• . Patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent.
• . Patient has been informed and agrees to pre- and post-procedure follow-up, including follow-up cardiac ultrasound and coronary angiogram or computed tomography (CT).
• . Patient is willing to be compliant with prescribed anticoagulant therapy (critical to preventing thrombus in the ATEV).

Exclusion criteria